Medacta Group reports 18.5% revenue growth in 2025

Reuters
02/03
Medacta Group reports 18.5% revenue growth in 2025

Medacta Group SA reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million (up 11.9% in constant currency), Knee EUR 284.1 million (up 20.7%), Extremities—including Shoulder and Sportsmed—EUR 72.1 million (up 46.2%), and Spine EUR 57.0 million (up 12.2%). The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2269966_en), on February 03, 2026, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10